KR850005498A - 면역화 외부표면 ebv 비루스성 단백질의 제조방법 - Google Patents

면역화 외부표면 ebv 비루스성 단백질의 제조방법 Download PDF

Info

Publication number
KR850005498A
KR850005498A KR1019850000544A KR850000544A KR850005498A KR 850005498 A KR850005498 A KR 850005498A KR 1019850000544 A KR1019850000544 A KR 1019850000544A KR 850000544 A KR850000544 A KR 850000544A KR 850005498 A KR850005498 A KR 850005498A
Authority
KR
South Korea
Prior art keywords
acc
cca
aca
aat
ccc
Prior art date
Application number
KR1019850000544A
Other languages
English (en)
Inventor
키에프(외 3) 엘리오트
Original Assignee
알렉산더 이 샤프
더 유니버시티어브 시카고
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉산더 이 샤프, 더 유니버시티어브 시카고 filed Critical 알렉산더 이 샤프
Publication of KR850005498A publication Critical patent/KR850005498A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/224—Herpes related

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

면역화 외부표면 EBV 비루스성 단백질의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 면역화 외부표면 EBV 비루스성 단백질을 코드화하는 DNA를 함유하는 벡터를 , 면역화 외부표면 EBV 비루스성 단백질을 발형시키기에 적합한 생리학적 활성물질에 주입시킴을 특징으로 하여, 면역화 외부표면 EBV 비루스성 단백질을 제조하는 방법.
  2. 제1항에 있어서, 면역화 외부표면 EBV 비루스성 단백질이 EBV DNA의 2.8kb 단편에 대해 코드화되는 방법.
  3. 제2항에 있어서, EBV DNA가 다음과 같은 뉴클레오타이드 서열을 갖는 방법:
    ATG GAG GCA GCC TTG CTT GTG TGT CAG TAC ACC ATC CAG AGC CTG ATC CAT CTCACG GGT GAA GAT CCT GGT TTT TTC AAT GTT GAG ATT CCG GAA TTC CCA TTT TACCCC ACA TGC AAT GTT TGC ACG GCA GAT GTC AAT GTA ACT ATC AAT TTC GAT GTCGGG GGC AAA AAG CAT CAA CTT GAT CTT GAC TTT GGC CAC CTG ACA CCC CAT ACGAAG GCT GTC TAC CAA CCT CGA GGT GCA TTT GGT GCA TCA GAA AAT GCC ACC AAT CTC TTT CTA CTG GAG CTC CTT GGT GCA GGA GAA TTG GCT CTA ACT ATG CGG TCT AAG AAG CTT CCA ATT AAC GTC ACC ACC GGA GAG GAG CAA CAA GTA AGC CTG GAA TCT GTA GAT GTC TAC TTT CAA GAT GTG TTT GGA ACC ATG TGG TGC CAC CAT GCA GAA ATG CAA AAC CCC GTG TAC CTG ATA CCA GAA ACA GTG CCA TAC ATA AAG TGG GAT AAC TGT AAT TCT ACC AAT ACG AAT GCA GTA GTG AGG GCA CAG GGG CTG GAT GTC ACG CTA CCC TTA AGT TTG CCA ACG TCA GCT CAA GAC TCG AAT TTC AGC GTA AAA ACA GAA ATG CTC GGT AAT GAG ATA GAT ATT GAG TGT ATT ATG GAG GAT GGC GAA ATT TCA CAA GTT CTG CCC GGA GAC AAC AAA TTT AAC ATC ACC TGC AGT GGA TAC GAG AGC CAT GTT CCC AGC GGC GGA ATT CTC ACA TCA ACG AGT CCC GTG GCC ACC CCA ATA CCT GGT ACA GGG TAT GCA TAC AGC CGT CGGT CTG ACA CCA CGT CCA GTG TCA CGA TTT CTT GGC AAT AAC AGT ATC CTG TAC GTG TTT TAC TCT GGG AATGGA CCG AAG GCG AGC GGG GGA GAT TAC TGC ATT CAG TCC AAC ATT GTG TTC TCT GAT GAG ATT CCA GCT TCA CAG GAC ATC CCG ACA AAC ACC ACA GAC ATC ACA TAT GTG GGT GAC AAT GCT ACC TAT TCA GTG CCA ATG GTC ACT TCT GAG GAC GCA AAC TCG CCA AAT GTT ACA GTG ACT GCC TTT TGG GCC TGG CCA AAC AAC ACT GAA ACT GAC TTT AAG TGC AAA TGG ACT CTC ACC TCG GGG ACA CCT TCG GGT TGT GAA AAT ATT TCT GGT GCA TTT GCG AGC AAT CGC ACA TTT GAC ATT ACT GTC TCG GGT CTT GGC ACG ACG GCC CCC AAG ACA CTC ATT ATC ACA CGA ACG GCT ACC AAT GCC ACC ACA ACA ACC CAC AAG GTT ATA TTC TCC AAG GCA CCC GAG AGCACC ACC ACC TCC CCT ACC CCT ACC TTG AAT ACA ACT GGA TTT GCT GAT CCC AAT ACA ACG ACA GGT CTA CCC AGC TCT ACT CAC GTG CCT ACC AAC CTC ACC GCA CCT CCA AGC ACA GGC CCC ACT GTA TCC ACC GCG GAT GTC ACC AGC CCA ACA CCA GCC GGC ACA ACG TCA GGC GCA TCA CCG GTG ACA CCA AGT CCA TCT CCA TGG GAC AAC GGC ACA GAA AGT AAG GCC CCC GAC ATG ACC AGC TCC ACC TCA CCA GTG ACT ACC CCA ACC CCA AAT GCC ACC AGC CCC ACC CCA GCA GTG ACT ACC CCA ACC CCA AAT GCC ACC AGC CCC ACC CCA GCA GTG ACT ACC CCA ACC CCA AAT GCC ACC AGC CCC ACC TTG GGA AAA ACA AGT CCT ACC TCA GCA GTG ACT ACC CCA ACC CCA AAT GCC ACC AGC CCC ACC TTG GGA AAA ACA AGC CCC ACC TCA GCA GTG ACT ACC CCA ACC CCA AAT GCC ACC AGC CCC ACC TTG GGA AAA ACA AGC CCC ACC ATC GCA GTG ACT ACC CCA ACC CCA AAT GCC ACC GGC CCT ACT GTG GGA GAA ACA AGT CCA CAG GCA AAT GCC ACC AAC CAC ACC TTA GGA GGA ACA AGT CCC ACC CCA GTA GTT ACC AGC CAA CCA AAA AAT GCA ACC AGT GTT ACC ACA GGC CAA CAT AAC ATA ACT TCA AGT TCA ACC TCT TCC TG TCA CTG AGA CCC AGT TCA AAC CCA GAG ACA CTC AGC CCC TCC ACC AGT GAC AAT TCA ACG TCA CAT ATG CCT TTA CTA ACC TCC GCT CAC CCA ACA GGT GGT GAA AAT ATA ACA CAG GTG ACA CCA GCC TCT ATC AGC ACA CAT CAT GTG TCC ACC AGT TCG CCA GAA CCC CGC CCA GGC ACC ACC AGC CAA GCG TCA GGC CCT GGA AAC AGT TCC ACA TCC ACA AAA CCG GGG GAG GTT AAT GTC ACC AAA GGC ACG CCC CCC CAA AAT GCA ACG TCG CCC CAG GCC CCC AGT GGC CAA AAG ACG GCG GTT CCC ACG GTC ACC TCA ACA GGT GGA AAG GCC AAT TCT ACC ACC GGT GGA AAG CAC ACC ACA GGA CAT GGA GCC CGG ACA AGT ACA GAG CCC ACC ACA GAT TAC GGC GGT GAT TCA ACT ACG CCA AGA CCG AGA TAC AAT GCG ACC ACC TAT CTA CCT CCC AGC ACT TCT AGC AAA CTG CGC CCC CGC TGG ACT TTT ACG AGC CCA CCG GTT ACC ACA GCC CAA GCC ACC GTG CCA GTC CCG CCA ACG TCC CAG CCC AGA TTC TCA AAC CTC TCC ATG CTA GTA CTG CAG TGG GCC TCT CTG GCT GTG CTG ACC CTT CTG CTG CTG CTG GTC ATG GCG GAC TGC GCC TTT AGG CGT AAC TTG TCT ACA TCC CAT ACC TAC ACC ACC CCA CCA TAT GAT GAC GCC GAG ACC TAT GTA
  4. 제2항에 있어서, 면역화 외부표면 EBV 비루스성 단백질이 다음과 같은 아미노산 서열을 갖는 방법:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850000544A 1984-01-30 1985-01-29 면역화 외부표면 ebv 비루스성 단백질의 제조방법 KR850005498A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57535284A 1984-01-30 1984-01-30
US575,352 1984-01-30
US06/633,558 US4707358A (en) 1984-01-30 1984-07-23 Vaccine against Epstein-Barr Virus
US633,558 1984-07-23

Publications (1)

Publication Number Publication Date
KR850005498A true KR850005498A (ko) 1985-08-26

Family

ID=27076676

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850000544A KR850005498A (ko) 1984-01-30 1985-01-29 면역화 외부표면 ebv 비루스성 단백질의 제조방법

Country Status (3)

Country Link
US (1) US4707358A (ko)
EP (1) EP0151079A3 (ko)
KR (1) KR850005498A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130122227A (ko) * 2012-04-30 2013-11-07 (주)바이오니아 엡스타인-바 바이러스 검출용 키트 및 이를 이용한 엡스타인-바 바이러스의 검출방법

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173254B1 (en) * 1984-08-23 1991-07-24 Hans Joachim Wolf Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens
EP0234871A3 (en) * 1986-02-28 1988-10-12 Merck & Co. Inc. Regulatable expression of recombinant proteins in yeast
EP0234862A3 (en) * 1986-02-28 1988-10-05 Merck & Co. Inc. Expression of recombinant proteins in yeast
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
EP0260012A1 (en) * 1986-09-02 1988-03-16 Merck & Co. Inc. Promoter for expression of heterologous proteins in mammalian cells
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
DE3706233A1 (de) * 1987-02-26 1988-09-08 Behringwerke Ag Immunogene fusionsproteine, die epstein-barr-virusproteine enthalten
IE873041L (en) * 1987-11-11 1989-05-11 Ailbe Brennan Viral antigens, diagnostic assay therefor and vaccines¹containing them
WO1990004176A1 (en) * 1988-10-03 1990-04-19 Scripps Clinic And Research Foundation THE RECEPTOR BINDING REGION OF EBVgp350
AU640430B2 (en) * 1989-11-24 1993-08-26 Council Of The Queensland Institute Of Medical Research, The Im peptides
EP0585216A1 (en) * 1989-11-24 1994-03-09 The Council Of The Queensland Institue Of Medical Research Im peptides
DE69128622T2 (de) * 1990-06-29 1998-04-23 Du Pont Test zum nachweis und/oder quantifizierung einer antikörperreaktion eines säugetiers gegen epstein-barr-virus-membranantigen
US20070202127A1 (en) * 1993-06-07 2007-08-30 Duke University Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6518013B1 (en) 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US7888458B1 (en) * 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
MY114769A (en) * 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US7273613B1 (en) 1997-01-13 2007-09-25 The Board of Regents, The University of Oklahoma Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
KR101205064B1 (ko) 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
CA2630218A1 (en) * 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP2631240A1 (en) * 2009-05-22 2013-08-28 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of Cytomegalovirus and Epstein-Barr virus
US20210115113A1 (en) * 2017-04-28 2021-04-22 City Of Hope Epstein-barr virus antibodies and uses thereof
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE46188T1 (de) * 1984-05-24 1989-09-15 Merck & Co Inc Positionsspezifische proteolyse mittels renin.
EP0173254B1 (en) * 1984-08-23 1991-07-24 Hans Joachim Wolf Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130122227A (ko) * 2012-04-30 2013-11-07 (주)바이오니아 엡스타인-바 바이러스 검출용 키트 및 이를 이용한 엡스타인-바 바이러스의 검출방법

Also Published As

Publication number Publication date
EP0151079A3 (en) 1987-06-24
US4707358A (en) 1987-11-17
EP0151079A2 (en) 1985-08-07

Similar Documents

Publication Publication Date Title
KR850005498A (ko) 면역화 외부표면 ebv 비루스성 단백질의 제조방법
ES2170065T3 (es) Modulacion de la proteina quinasa c por oligonucleotidos.
AU6180190A (en) Fast process for detecting and/or identifying a single base on a nucleic acid sequence and its applications
DE69023934D1 (de) Substanz PF 1022, Verfahren zu ihrer Herstellung und diese Substanz enthaltende anthelmintische Zusammensetzung.
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
ATE48278T1 (de) Verfahren zur herstellung von 2'desoxyadenosinverbindungen.
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
FR2728264B1 (fr) Purification d'adn par formation de triple helice avec un oligonucleotide immobilise
TW336250B (en) Heat curing silicone rubber composition
EP0002322A3 (en) Improved triester process for the synthesis of oligonucleotides
IT8521215A0 (it) Processo per la preparazione dell'acido cis-5-fluoro-2-metil-1-(4-metiltiobenziliden)-indenil-3-acetico.
AU4149485A (en) Process for quenching fluorescence and new cationic or amphoteric aromatic nitro compounds
DE3772308D1 (de) Verfahren zur herstellung von retinoylchloriden.
KR870001204A (ko) 로오다닌 유도체의 제조방법
DE3872435D1 (de) Verfahren zur herstellung von 2.3-dimethylbuten-1 aus propen.
IE45285L (en) Polyribonucleotides.
PT83472B (pt) Processo para a preparacao de composicoes anti-inflamatorias aperfeicoadas contendo piroxicamo
IT1113343B (it) Processo per la preparazione di 1,5-dimetibicicl(3.2.1)ottanol-8
EP0215949A4 (en) PRODUCTION PROCESS 16-SUBSTITUTED PROSTAGLANDINE-E.
KR850005435A (ko) 3-알콕시-2-(n-피롤리디노)-n-피리미디닐-또는 n-피라지닐 프로필아민의 제조방법
OA08076A (fr) Acide dihdro-5,6-4H-cyclopenta[b] thiophènecarboxyliques-6, procédés de préparation.
JPS5441891A (en) Adenine nucleotide derivative
IT8120245A0 (it) Processo per la preparazione di 11-(2'-sostituito)-acetil-5,11-diidro-6h-pirido-(2,3-b)(1,4)-benzodiazepin-6-oni.
ATA180785A (de) Verfahren zur herstellung von oxazino-(5,6-c)-1,2-benzothiazin-6,6-dioxid
PT83116B (pt) Processo para a preparacao de acidos 5-cloro-s-triazolo{4,3-a}-piridino-7-carboxilicos

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application